•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
Aclaris Therapeutics, Inc. (ACRS) – What Are Analysts Saying About This Stock?
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRS
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates